Skip to main content

Table 3 Overall survival: multivariate proportional hazard analysis

From: Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics

Variable Hazard ratio 95% CI P value
Treatment: decitabine vs TC 0.799 (0.653–0.978) 0.0296
Sex: male vs female 1.125 (0.912–1.388) 0.2703
Age group    
 70–74 vs <70 years 1.311 (1.004–1.711) 0.0468
 ≥75 vs <70 years 1.560 (1.198–2.032) 0.0010
Baseline cytogenetic risk: intermediate vs poor 0.699 (0.565–0.865) 0.0010
Type of AML: de novo vs secondary 1.110 (0.893–1.380) 0.3452
Baseline ECOG PS: 0 or 1 vs 2 0.771 (0.607–0.978) 0.0321
Geographic region [8]    
 Eastern Europe vs North America/Australia 1.118 (0.849–1.473) 0.4263
 Western Europe vs North America/Australia 0.727 (0.523–1.010) 0.0572
 Asia vs North America/Australia 1.047 (0.728–1.505) 0.8052
 Western Europe vs Eastern Europe 0.650 (0.482–0.877) 0.0048
 Western Europe vs Asia 0.694 (0.472–1.021) 0.0637
Baseline bone marrow blast: >50% vs ≤50% 1.355 (1.099–1.672) 0.0045
Baseline platelets (109/L)a 0.775 (0.663–0.907) 0.0015
Baseline WBC (109/L)b 1.256 (1.045–1.509) 0.0151
  1. AML, acute myeloid leukemia; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; TC, patient's choice of treatment with physician's advice; WBC, white blood cell counts.
  2. aHazard ratio less than 1 indicates lower risk associated with each additional 100 × 109/L in baseline platelet counts.
  3. bHazard ratio greater than 1 indicates higher risk associated with each additional 25 × 109/L in baseline WBC counts.